The best in class funds emerged victorious from the crisis

The best in class funds emerged victorious from the crisis

After the extraordinary event of the coronavirus that impacted populations, economies and markets in recent months, the performance in May 2020 of our best in class funds stands out, especially when compared with those of the main peers.

The secret of the success is has been revealed directly by the management team: "we maintain a long-term investment horizon and identify the main structural trends driving growth".

Here following the comparative analysis with the main category peers.


Pharus Sicav Absolute Return

Pharus Sicav Absolute Return (white line) vs. peers (grey area)


Pharus Sicav Best Regulated Companies

Pharus Sicav Best Regulated Companies (white line) vs. peers (grey area)


Pharus Sicav Biotech

Pharus Sicav Biotech (white line) vs. peers (grey area)


Pharus Sicav Next Revolution

Pharus Sicav Next Revolution (white line) vs. peers (grey area)


Pharus Sicav Target

Pharus Sicav Target (white line) vs. peers (grey area)

Information message - The information in this message is produced for information purposes only and therefore does not qualify as offer or recommendation or solicitation to buy or sell securities or financial instruments in general, financial products or services or investment, nor an exhortation to carry out transactions related to a specific financial instrument.
The contents of this informative message are the result of the free interpretation, evaluation and appreciation of Pharus Asset Management SA and constitute simple food for thought.
Any information and data indicated have a purely informative purpose and do not in any way represent an investment advisory service: the resulting operational decisions are to be considered taken by the user in full autonomy and at his own exclusive risk.
Pharus Asset Management SA dedicates the utmost attention and precision to the information contained in this message; nevertheless, no liability shall be accepted for errors, omissions, inaccuracies or manipulations by third parties on what is materially processed capable of affecting the correctness of the information provided and the reliability of the same, as well as for any result obtained using the said information.
It is not permitted to copy, alter, distribute, publish or use these contents on other sites for commercial use without the specific authorization of Pharus Asset Management SA.
Back to all news

Related News


Biotech: a stop that will not last


What impact will inflation have on corporate earnings?


China: opportunities within the revolution


The BoLe Chronicle | August 2021


Post-COVID, new opportunities for Biotech


Pharus Sicav Best Regulated Companies distributes the third dividend


The BoLe Chronicle | May 2021


Inflation: temporary or not?


The BoLe Chronicle | April 2021